|Slideshows|October 30, 2020

10 Salient Points About Migraine and Psychiatric Comorbidity

Author(s)Todd A. Smitherman, PhD, Donald B. Penzien, PhD, Jeanetta C. Rains, PhD

Where do migraines and psychiatric disorders intersect? Learn more.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

COMP360 Psilocybin in Treatment-Resistant Depression: Insights From Gus Alva, MD, DFAPA

ByGustavo Alva, MD, DFAPA

July 11th 2026

Postpartum Depression: Zuranolone, Emerging Therapies, and Screening for Birth Trauma

ByKatie Unverferth, MD

July 11th 2026

Consensus Guidelines for IV Ketamine: Safe Clinical Practice

BySandhya Prashad, MD

July 9th 2026

Addiction Pharmacotherapy in Bipolar Disorder: Rethinking Comorbidity

ByJoseph F. Goldberg, MD,Michael J. Ostacher, MD, MPH

July 1st 2026

Metabolic Risk, Residual Insomnia, and Seltorexant

ByJane Tiller, MD

June 25th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

10 Salient Points About Migraine and Psychiatric Comorbidity

Related Content

COMP360 Psilocybin in Treatment-Resistant Depression: Insights From Gus Alva, MD, DFAPA

Postpartum Depression: Zuranolone, Emerging Therapies, and Screening for Birth Trauma

Consensus Guidelines for IV Ketamine: Safe Clinical Practice

Addiction Pharmacotherapy in Bipolar Disorder: Rethinking Comorbidity

Metabolic Risk, Residual Insomnia, and Seltorexant

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Vol 43, Issue 7 - Interactive

Psychedelics, Orexin Blockers, and More: Inside the Diverse New Pipeline for Depression

Beyond Deprescribing: A Formula for Excellent Clinical Care

Long-Acting Injectables in Schizophrenia: Closing the Gap Between Evidence and Practice

VY1706 for Treatment of Alzheimer Disease Shows Tau Reductions and Favorable Tolerability